 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP has announced an exclusive option agreement and research collaboration with Kansas State University K-State to develop zinc nanoparticle ZNP mRNA vaccines. The ZNP technology replaces the lipid-nanoparticle LNP technology in current COVID-19 vaccines. 